Compare CD20 monoclonal antibodies. View important safety information, ratings, user reviews, popularity and more.

In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.

Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab.

Of the novel anti-CD20 antibodies, only obinutuzumab has shown consistently improved efficacy over rituximab in randomized pivotal trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 3 GALLIUM trial demonstrated significant improvements in progression-free survival wi …

Apr 3, 2025 · The anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab are used to treat multiple sclerosis, and the anti-CD19 monoclonal antibody inebilizumab is used to treat neuromyelitis optica spectrum disorder; they work by binding to B cells and causing them to be eliminated. These therapeutic antibodies were designed to have …

May 24, 2012 · The oncologist recommends treatment with the anti-CD20 monoclonal antibody rituximab in combination with a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone...

Apr 6, 2025 · Introduction: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding of disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS).

Anti-CD20 mAbs have emerged as an essential treatment option for patients with relapsing MS. Clinicians must be aware that anti-CD20 mAbs differ in their structures, target epitopes, dosing regimens, route of administration, and mechanisms of B cell depletion.

Anti-CD20 monoclonal antibodies are a class of drugs used to treat patients with previously untreated chronic lymphocytic leukemia. Learn about uses, side effects, and drug names.